

Schizophrenia and its Treatment

Shatakshi Sharma*

*Department of Genetics, Vellore Institute of Technology, Vellore, India

Review Article

Received: 10/08/2016

Revised: 19/08/2016

Accepted: 26/09/2016

*For Correspondence

Shatakshi Sharma,
Department of Genetics, Vellore
Institute of Technology, Vellore,
India

Keywords: Schizophrenia,
Treatment, Hereditary, Mental
status

E-mail:
mailme_shatakshi@rediffmail.com

ABSTRACT

Schizophrenia is a genuine issue which influences how a man considers, feels and acts. Somebody with schizophrenia may experience issues recognizing what is genuine and what is nonexistent; might be lethargic or pulled back; and may experience issues communicating typical feelings in social circumstances. Schizophrenia is a testing issue that makes it hard to recognize what is genuine and unbelievable, think unmistakably, oversee feelings, identify with others, and capacity ordinarily. Be that as it may, that doesn't mean there isn't trust. Schizophrenia can be effectively overseen. The initial step is to recognize the signs and manifestations. The second step is to look for help immediately. With the right treatment and backing, a man with schizophrenia can lead a glad, satisfying life.

Schizophrenia is a mind issue that influences the way a man acts, considers, and sees the world. Individuals with schizophrenia regularly have an adjusted view of reality. They may see or hear things that don't exist, talk in interesting or confounding ways, trust that others are attempting to mischief them, or feel like they're as a rule always viewed. This can make it hard to arrange the exercises of day by day life, and individuals with schizophrenia may pull back from the outside world or carry on in perplexity and apprehension.

In spite of the fact that schizophrenia is an interminable issue, there is help accessible. With bolster, medicine, and treatment, numerous individuals with schizophrenia can work freely and live satisfying lives.

SIGNS AND SYMPTOMS

There are five sorts of side effects normal for schizophrenia: fancies, pipedreams, muddled discourse, disarranged conduct, and the supposed "negative" side effects. Be that as it may, the signs and side effects of schizophrenia change drastically from individual to individual, both in example and seriousness. Not each individual with schizophrenia will have all indications, and the side effects of schizophrenia may likewise change after some time. Delusions of persecution, Delusions of reference, Delusions of grandeur, and Delusions of control are the common symptoms.

CAUSES

The reasons for schizophrenia have been the subject of much open deliberation, with different components proposed and marked down or altered. The dialect of schizophrenia exploration under the medicinal model is logical. Such studies propose that hereditary qualities, pre-birth advancement, early environment, neurobiology and mental and social procedures are critical contributory components. The causes of schizophrenia, like all mental disorders, are not completely understood or known at this time.

There is no known single reason for schizophrenia. Numerous sicknesses, for example, coronary illness, result from an interchange of hereditary, behavioral and different components, and this might be the situation for schizophrenia too. Researchers don't yet see the majority of the components important to deliver, yet every one of the instruments of present day biomedical examination are being utilized to scan for qualities, basic minutes in mental health, and different variables that may prompt the disease.

Furthermore, components, for example, pre-birth troubles like intrauterine starvation or viral contaminations, perinatal intricacies, and different nonspecific stressors, appear to impact the improvement of schizophrenia. In any case, it is not yet seen how the hereditary inclination is transmitted, and it can't yet be precisely anticipated whether a given individual will or won't build up the turmoil.

TREATMENT OF SCHIZOPHRENIA

Schizophrenia requires deep rooted treatment, notwithstanding when manifestations have died down. Treatment with solutions and psychosocial treatment can deal with the condition. Amid emergency periods or times of extreme manifestations, hospitalization might be important to guarantee wellbeing, legitimate nourishment, sufficient rest and essential cleanliness. Solutions are the foundation of schizophrenia treatment. Be that as it may, on the grounds that prescriptions for schizophrenia can bring about genuine however uncommon reactions, individuals with schizophrenia might be hesitant to take them.

Most people with schizophrenia need some type of everyday living help. Numerous people group have projects to individuals with schizophrenia with employments, lodging, self-improvement gatherings and emergency circumstances. A caseworker or somebody on the treatment group can discover assets. With proper treatment, a great many people with schizophrenia can deal with their condition.

A specialist or psychological wellness supplier will check mental status by watching appearance and aura and getting some information about contemplations, inclinations, fancies, mind flights, substance misuse, and potential for savagery or suicide.

DIAGNOSIS

Finding of schizophrenia includes precluding other emotional wellness issue and establishing that manifestations aren't because of substance misuse, prescription or a therapeutic condition. Moreover, a man must have no less than two of the accompanying side effects more often than not amid a one-month time frame, with some level of unsettling influence being available more than six months.

Recuperation from schizophrenia is a deep rooted process. It doesn't mean you won't encounter any more difficulties from the ailment or that you'll generally be sans manifestation. What it means is that you are figuring out how to deal with your side effects, building up the bolster you require, and making a delightful, reason driven life.

Fruitful treatment for schizophrenia expects to ease current side effects, anticipate future maniacal scenes, and reestablish your capacity to work and appreciate an important life. A schizophrenia treatment arrange for that joins prescription with self-improvement, strong administrations, and treatment is the best approach.

REFERENCES

1. Dana B. DiBenedetti, et al. Assessing Patient and Caregiver Experiences with Symptoms and Behaviors Associated with Schizophrenia. *J Depress Anxiety*. 2016;5:240.
2. Michele Ribolsi, et al. Non Invasive Brain Stimulation to Improve Metaphoric Speech Processing in Schizophrenia: A Pilot Study. *J Neurol Neurophysiol*. 2016;7:375.
3. Iqbal MZ and Ejaz M. Case Study of Schizophrenia (Paranoid). *J Clin Case Rep*. 2016;6:779.
4. Domenico De Berardis. Second Generation Long-acting Injectable Antipsychotics as a First-line Treatment of First Episode Schizophrenia: Lights and Shadows. *J Neuropsychopharmacol Mental Health*. 2016.
5. Stefano Barlati, et al. Autism Spectrum Disorder and Schizophrenia: Do They Overlap? *Int J Emerg Ment Health*. 2016;18:318.
6. Mamo ES, et al. Medication Adherence among Patients with Schizophrenia Treated with Antipsychotics at Adama Hospital, East Shoa Zone, Oromia Regional State. *Adv Pharmacoepidemiol Drug Saf*. 2016;5:2.
7. Sadia Shakeel, et al. Pharmacy Students Attitude and Stigmatization of People with Schizophrenia in Pakistan. *J Bioequiv Availab*. 2016.
8. Carlos Andres Penaherrera and Maria Carolina Duarte. Schizophrenia and Social Cognition: A Review of Concepts and Treatment Options. *J Socialomics*. 2016;5:150 .
9. Prasenjit Ray and CRJ Khess. Level of Insulin Resistance in Schizophrenia Patients and Its Association with Treatment with Antipsychotics. *J Neuropsychopharmacol Mental Health*. 2016.

10. Valérie Bonnard, et al. Emotional Face Perception: Event-Related Potentials (ERPS) Contribution to Differentiate Schizophrenia and Autism Spectrum Disorders in Adolescents. *Autism Open Access*. 2015.
11. Keiko Ikemoto and Akiyoshi Nishimura. Lectin-Positive Spherical Deposits (SPD) Detected in the Molecular Layer of Hippocampal Dentate Gurus of Schizophrenia. *J Neurol Neurophysiol*. 2015;6:328.
12. Lucie Bartova, et al. Ultra-High-Dose Long-Acting Injectable Aripiprazole in Chronic Refractory Schizophrenia: A Case Report. *J Clin Toxicol*. 2015;5:270.
13. Sukanchan Palit. The Challenge of Overcoming Schizophrenia and a True Vision for the Future. *Neurochem Neuropharm*. 2015.
14. James P. Kelleher. The Evolution of Schizophrenia Research and Treatment. *Int J Emerg Ment Health* 2015;17:280.
15. Maria Chiara Pino, et al. Effect of Gaze Direction on Orienting of Attention in Patients with Schizophrenia: Attention or Social Cognition Deficit? *J Depress Anxiety*. 2015;4:200.
16. Homero Daniel Hernandez-Yáñez, et al. Family Support and Adherence to Treatment in Patients Diagnosed with Schizophrenia in Tabasco, Mexico: A Case- Series Study. *J Psychiatry*.2015.
17. Kerime Bademli. Peer to Peer Support in Schizophrenia. *Int J Emerg Ment Health*.2015;17: e239.
18. Terri Morgan. Excerpts from The Genetic Lottery: A Novel Look at Schizophrenia. *Int J Emerg Ment Health*. 2015;17:233.
19. Inanaga K. Recovery from Schizophrenia with Bioactive Substances in *Heridium erinaceum*. *Int J Sch Cog Psychol*.2015;S1:003.
20. Jianqing Tao, et al. Effects of Cognitive Rehabilitation Training on Schizophrenia: 2 Years of Follow-Up. *J Psychiatry*.2015.
21. Kamal SM and Dine SE. Neuroplasticity and Antipsychotics in Treatment of Schizophrenia. *J Neurol Disord*.2015;3:232
22. Fandino-Franky J. Editorial on Neuroplasticity and Antipsychotics in Treatment of Schizophrenia. *J Neurol Disord*.2015;3:e115.
23. Kerime Bademli. What to Know about Schizophrenia Caregiver Support. *Int J Emerg Ment Health*. 2015;17:218.
24. Tamas Tenyi, et al. The Importance of Research on the Relatives of Schizophrenia Patients? Towards Endophenotypic Markers. *Int J Emerg Ment Health*.2015;17: e211.
25. Elsayed MA. Schizophrenia in Hollywood Movies. *J Mass Communicat Journalism*.2015; 5:256.
26. Keiko Ikemoto. Dopamine Hypothesis is linked with Neural Stem Cell (NSC) Dysfunction Hypothesis by D-Cell Hypothesis (Trace Amine Hypothesis) in Etiology of Schizophrenia. *Biochem Physiol*. 2015;4:152.
27. Sahar Mohamed Kamal and Shams El Dine. Spotlights on Pharmacogenetics of Schizophrenia and Depressed Mood. *Gene Technol*.2015;4:121.
28. Amira Alshowkan, et al. Factors Affecting the Quality of Life for People with Schizophrenia in Saudi Arabia: A Qualitative Study. *j Psychiatry*.2015.
29. Panagiota Korenis, et al. Schizophrenia with Somatic Delusions: A Case Report. *J Psychiatry*. 2015
30. Ahmed Naguy and Haya Al-Mutairi. Add-on Atomoxetine Mitigated Different Symptom Domains in a Case of Early- Onset Schizophrenia. *J Psychiatry*.2015
31. Bekir Kocazeybek and Fatma Kalayci. Assessment of Association between Schizophrenia and Chlamydiaceae Using Hill Criteria. *J Psychiatry*.2015
32. Jin Zhang,et al. Interaction between MicroRNA-7 and its Target Genes in Schizophrenia Patients. *j Psychiatry*.2015.
33. Ariela Gigi, et al. Visual Impairment Affects the Perception of Reality: Visual Processing Deficits among Adolescents with Schizophrenia. *J Psychiatry*.2015.
34. Chieffi S, et al. Vulnerability to Distraction in Schizophrenia. *J Psychiatry*.2015.
35. Lionella Palego, et al. Sulfur Metabolism and Sulfur-Containing Amino Acids Derivatives ? II: Autism Spectrum Disorders, Schizophrenia and Fibromyalgia. *Biochem Pharmacol (Los Angel)*.2015;4: 159
36. Felix-Martin Werner and Rafael Coveñas. Clinical Efficacy of Antipsychotic Drugs in the Treatment of Schizophrenia. *J Cytol Histol*.2015;S4-013

37. Zebiba Nassir Hussien, et al. Prevalence and Associate Factors of Suicidal Ideation and Attempt among People with Schizophrenia at Amanuel Mental Specialized Hospital Addis Ababa, Ethiopia. *J Psychiatry*.2015.
38. Mamta Singh, et al. Hypothalamic-Pituitary-Adrenal (HPA) Axis Functioning among Patients with Schizophrenia: A Cross Sectional Comparative Study. *J Psychiatry*.2015.
39. Kaberi Bhattacharya. Cognitive Function in Schizophrenia: A Review. *J Psychiatry*.2015.
40. Ebru Oztepe Yavasci, et al. Prediction of Depression in Schizophrenia: Can serum Levels of BDNF or EGF Help us?. *J Psychiatry*.2014.
41. Chunlan Yang, et al. A Review: Detecting Alterations of Brain Connectivity in Schizophrenia based on Structural MRI. *J Psychiatry*.2014.
42. Chang Hyun Jang, et al. A Case of Clozapine-Resistant Schizophrenia Associated With a Large Arachnoid Cyst in the Left Sylvian Fissure. *J Psychiatry*.2014.
43. Saeed Ahmed, et al. Nicotine Addiction in Schizophrenia, Availability of Better Treatment Options as are in General Population. *Int J Emerg Ment Health*.2015; 17: 135.
44. Mélanie Langlois, et al. Thirty Days without a Bite: Wernicke?s Encephalopathy in a Patient with Paranoid Schizophrenia. *J Neurol Disord*.2014; 2: 182.
45. Matthew E Ryan and Trish Melzer. Delusions in Schizophrenia: where are we and where Do we need to go?. *Int J Sch Cogn Psychol*.2014; 1:115.
46. Khalid W Al Quliti. A Case Study of Partial Seizure with Secondary Generalization Induced by Clozapine in Patient with Treatment Resistant Schizophrenia. *Brain Disord Ther*. 2014; 3:145.
47. Aurelie Millier, et al. Reasons for Aripiprazole Discontinuation in Schizophrenia – A Retrospective. *J Neurol Neurophysiol*.2014; 5:226
48. Zsuzsa Szombathyne Meszaros, et al. Smoking Severity and Functional MRI Results In Schizophrenia: A Case-Series. *J Addict Res Ther*.2014; 5:
49. Felix-Martin Werner. Brain Centers Involved in Schizophrenia. *J Cytol Histol*.2014;5: i101
50. Correlation between Anxiety and Personality in Caregivers for Patients with Schizophrenia. *J Psychiatry*.2014.
51. A-La Park. Exploring the Economic Implications of a Group-Based Lifestyle Intervention for Middle-Aged Adults with Chronic Schizophrenia and Co-Morbid Type 2 Diabetes. *J Diabetes Metab*.2014; 5:366.
52. Sorour Ahmadian, et al. D3 as a Possible Marker Based on D1-D4 Dopamine Receptors Expression in Paranoid Schizophrenia Patients. *J Mol Biomark Diagn*.2014;5:171.
53. Shahriar Gharibzadeh, et al. Reactivation of NMDA Receptors by Synaptic Reentry Reinforcement, a Probable Cause of Auditory Hallucination in Schizophrenia. *Brain Disord Ther*.2014;3:118.
54. Mary T Rosedale, et al. Transcranial Direct Current Stimulation to Enhance Cognition and Functioning in Schizophrenia. *J Nov Physiother*.2014;4:191
55. Luzny Jan and Jan Chalany. Clozapine for Treating Pharmacoresistant Schizophrenia among Elders. *J Clin Diagn Res*.2014;2:101
56. Miwako Sakai, et al. An Attempt of Non-human Primate Modeling of Schizophrenia with Neonatal Challenges of Epidermal Growth Factor. *J Addict Res Ther*.2014;5:170
57. Sean Hood. A Patient with a Pancreatic Endocrine Tumor develops Chronic Schizophrenia: Report of a Case. *J Clin Case Rep*.2013;4:328.
58. Jing Zhang, et al. A FDG-PET and fMRI Study on Glucose Metabolism and Hemodynamic Response during Visual Attentional Performance in Schizophrenia. *OMICS J Radiol*.2013;2:149.
59. Keiko Ikemoto. D-Neuron: Is it Ligand-Producing Neuron of Taar1? From Schizophrenia Research. *J Community Med Health Edu*.2013.
60. Shankar GS and Carol Yuan. Effects of 5HT2c Blockade of Dibenzodiazepines on Thyroid Levels in Patients with Schizophrenia or Schizoaffective Disorder. *J Autacoids*.2013;2:102
61. Ayden Jacob, et al. Abnormal Brain Circuitry and Neurophysiology Demonstrated by Molecular Imaging Modalities in Schizophrenia. *J Alzheimers Dis Parkinsonism*.2013;3:114.
62. Mubeen Khan and Udaya M Kabadi. Metabolic Challenges in Schizophrenia. *J Psychol Psychother*. 2013;3:115.
63. Bianca Andreica-Sandica. The Necessity of Family Type Interventions During First - Episode Psychosis in Schizophrenia. *J Trauma Treat*.2013;2:e111.

64. Satoru Yamagishi, et al. Spine Homeostasis as a Novel Therapeutic Target for Schizophrenia. *Clin Pharmacol Biopharm.*2013;S1: 001.
65. Peter Thomas Sandy and Tennyson Mgutshini. Integrating Religiosity into Motivational Interviewing and Nicotine Replacement Therapy for a Patient with Schizophrenia and Nicotine Addiction: Lessons from a Mental Health Service. *J Addict Res Ther.*2012.
66. Laia Mas-Expósito. Physical Health and Schizophrenia in Clinical Practice Guidelines and Consensus Statements. *J Addict Res Ther.*2012;S8:001.
67. Keiko Ikemoto. Are D-Neurons and Trace Amine-Associated Receptor, Type 1 Involved in Mesolimbic Dopamine Hyperactivity of Schizophrenia?. *Med Chem (Los Angeles).*2012.
68. Sandeep Grover, et al. Relapse of Tourette Syndrome with Clozapine in a Patient of Paranoid Schizophrenia. *J Clinic Case Reports.*2012;2:e112
69. Man C M Tsui. Review of the Effects of Yoga on People with Schizophrenia. *J Yoga Phys Ther.* 2012;S1-001.
70. Mahtab Karkhane Yousefi. A Review of Varenicline's Efficacy and Tolerability in Smoking Cessation Studies in Subjects with Schizophrenia. *J Addict Res Ther.*2011;S4.
71. Habtamu Kerebih and Matiwas Soboka . Prevalence of Common Mental Disorders and Associated Factors among Residents of Jimma Town, Southwest Ethiopia. *J Psychiatry.*2016.
72. Xiaoran Sun, et al. The Potential Role of Melatonin on Mental Disorders: Insights from Physiology and Pharmacology. *Bipolar Disord.* 2016.
73. Hidefumi Oga and Kouichi Yoshimasu. A Pilot Study of Self-Care Program of Mindful Life Approach for Improvements of Socially Problematic Behaviors of Children with Developmental Disorders through Caregivers. *J Psychol Psychother.*2016;6:245.
74. Tzipi Horowitz-Kraus. All Roads Lead to Rome? Distinct Neural Circuits in Different Developmental Disorders are Related to Reading Difficulties in Children. *Brain Disord Ther.*2015;4:197.
75. Miriam Castaldo. Susto: Etiology of Mental Disorders in Mothers and Children in Mexico. *J Preg Child Health.* 2015.
76. Alemayehu Tibebe and Kenfe Tesfay. Public Knowledge and Beliefs about Mental Disorders in Developing Countries: A Review. *J Depress Anxiety.*2015;S3:004.
77. Renata Marques de Oliveira. Factors Associated With Tobacco Dependence in People with Mental Disorders. *J Addict Res Ther.*2015;6:231.
78. Eman A Zaky, et al. Association of Second Hand Smoking with Mental Disorders in Children- An Egyptian Study. *J Psychol Abnorm Child.*2015;4:140.
79. Alexander M Ponizovsky and Ivonne Mansbach-Kleinfeld. Prevalence of Mental Disorders and Use of Services in an Immigrant Adolescent Population: Findings from a National Mental Health Survey. *J Child Adolesc Behav.*2015;3:176.
80. Nazanin Alavi. Outcome Study of Intensive Day Treatment for Children with Pervasive Developmental Disorders. *Autism Open Access.*2014;4:137.
81. Karhson DS, et al. Endocannabinoid signaling in social functioning: an RDoC perspective.2016; 27:169
82. Detke HC, et al. A 52-Week Study of Olanzapine with a Randomized Behavioral Weight Counseling Intervention in Adolescents with Schizophrenia or Bipolar I Disorder *J Child Adolesc Psychopharmacol.*2016.
83. Kageyama Y, et al. Search for plasma biomarkers in drug-free patients with bipolar disorder and schizophrenia using metabolome analysis. *Psychiatry Clin Neurosci.*2016.
84. Morita K, et al. Eye Movement as a Biomarker of Schizophrenia: Using an Integrated Eye Movement Score. *Psychiatry Clin Neurosci.*2016.
85. Gay O, et al. Cognitive control deficit in patients with first-episode schizophrenia is associated with complex deviations of early brain development. *J Psychiatry Neurosci.*2016;41:150267.
86. Scheinost D, et al. Does prenatal stress alter the developing connectome? *Pediatr Res.*2016;27.
87. Haider AS, et al. Autoimmune Schizophrenia? Psychiatric Manifestations of Hashimoto's Encephalitis. *Cureus.*2016;8:e672.

88. Scarff JR. Brexpiprazole: A New Treatment Option for Schizophrenia. *Innov Clin Neurosci.*2016; 13:26-29.
89. MacEwan JP, et al. Pharmaceutical Innovation in the Treatment of Schizophrenia and Mental Disorders Compared with Other Diseases *Innov Clin Neurosci.*2016;13:17-25.
90. Lang B, et al. Hunter I Control of cortex development by ULK4, a rare risk gene for mental disorders including schizophrenia *Sci Rep.*2016;6:31126.
91. Thomson A, et al. Fire-setting performed in adolescence or early adulthood predicts schizophrenia: a register-based follow-up study of pre-trial offenders. *Nord J Psychiatry.* 2016.
92. Charles L, et al. Conscious and unconscious performance monitoring: Evidence from patients with schizophrenia *Neuroimage.*2016;S1053-8119: 30532-30538.
93. Scotti-Muzzi E, et al. Schizo-obsessive spectrum disorders: an update. *CNS Spectr.*2016;27:1-15.
94. Uran P, et al. Premenstrual syndrome health-related quality of life and psychiatric comorbidity in a clinical adolescent sample: a cross-sectional study. *Int J Psychiatry Clin Pract.*2016;27:1-5.
95. Pan S, et al. Serum high-sensitivity C-reactive protein: A delicate sentinel elevated in drug-free acutely agitated patients with schizophrenia. *Psychiatry Res.*2016;246:89-94.
96. Hurtado MM, et al. Are executive functions related to emotional intelligence? A correlational study in schizophrenia and borderline personality disorder. *Psychiatry Res.*2016;246:84-88.
97. Cotovio G, et al. Barahona-Correa B. Clozapine-Resistant Schizophrenia Treated With Ultra-brief Pulse, Unilateral Electroconvulsive Therapy. *J ECT.*2016.
98. Kahn JR, et al. Post-9/11 Veterans and Their Partners Improve Mental Health Outcomes with a Self-directed Mobile and Web-based Wellness Training Program: A Randomized Controlled Trial. *J Med Internet Res.*2016;18:e255.
99. Pos K, et al. The effect of childhood trauma and Five-Factor Model personality traits on exposure to adult life events in patients with psychotic disorders. *Cogn Neuropsychiatry.*2016;28:1-13.
100. Costa EC, et al. Resource Loss Moderates the Association Between Child Abuse and Current PTSD Symptoms Among Women in Primary-Care Settings. *J Interpers Violence.*2016.